In a drive to reduce high cervical-cancer rates in Nigeria, a nonprofit organization co-founded by Stanford oncology researcher Ami Bhatt, MD, PhD, has enlisted the imaginative assistance of an educational comic book.
Stanford and SLAC researchers are developing new technology to dramatically reduce the duration of radiation therapy and its treatment side effects.
The leading cause of death in the U.S. is shifting from heart disease to cancer at varying paces across the country, according to Stanford research.
A novel immunotherapy appears safe for use in patients with non-Hodgkin’s lymphoma. Here, a Northern California man shares his experience in the study.
A Stanford team has developed an algorithm that uses data about tumors to identify new classifications that can provide information about patient outcomes
A Stanford-designed computer algorithm helps doctors predict the lifespan of patients with metastatic cancer by looking for clues in their own exam notes.
In a new study, a team of researchers has examined the relationship between protein binding to DNA and the development of cancer.
A stage IV cancer patient discusses what it means to live well with serious illness at Stanford Medicine's Jonathan King Lecture series.
A new generation of brain cancer patients are working to improve care and connect and support patients using social media and advocacy.
Stanford researchers have learned that cancer cells can batter their way into new territory, rather than relying on dissolving chemicals.
Cancerous tumors cause disease in two ways: they grow and spread. But a new immune therapy approach may be able to target both problems simultaneously.
In this essay that originally appeared in Months to Years, writer Mal Schoen describes how he was diagnosed with colon cancer.
Hiding mRNA messages in CARTs — positively charged degradable vehicles —smuggles them across the cell membrane and can 'vaccinate' against cancer in mice.
Online outreach and low-cost testing can encourage relatives of cancer patients to assess their own cancer risk through 'cascade' testing.
Mapping the geography of the immune response in triple negative breast cancers predicts patient survival and sheds light onto new aspects of tumor biology.
The true driver mutations of cancer are almost always common to all metastases in an individual, according to a Stanford scientist and other researchers.